Search

Displaying results 5651 - 5660 of 10000 in total
  1. Drug

    Recombinant Human Thrombopoietin

    go.drugbank.com/drugs/DB16364
    Investigational

    Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets. … [A225691, A225696] This drug is used in the treatment of thrombocytopenia.

  2. Drug

    Rocatinlimab

    go.drugbank.com/drugs/DB18809
    Investigational

    Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. … The drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis.

  3. Drug

    Probiorinse

    go.drugbank.com/drugs/DB15870
    Experimental

    [L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193] … Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.

  4. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug. … Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

  5. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance

  6. Drug

    NLX-P101

    go.drugbank.com/drugs/DB05924
    Experimental

    The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), … NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease.

  7. Drug

    TG-100801

    go.drugbank.com/drugs/DB05075
    Investigational

    It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological … TG100801 is a topically applied kinase inhibitor in macular degeneration patients.

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Alizapride

    go.drugbank.com/drugs/DB01425
    Investigational

    Alizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects. … This kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, including that which may occur postoperatively.

    Categories: Heterocyclic Compounds, 1-RingProducts: ALIPRID ®, PLITICAN® GOTAS
  9. Drug

    Deracoxib

    go.drugbank.com/drugs/DB11395
    ExperimentalVet approved

    Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. … It is sold in tablets, which have added beefy flavour to increase palatability.

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    V591

    go.drugbank.com/drugs/DB16438
    Investigational

    The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery[L30593]. … Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I clinical trials (NCT04498247)[L30593].